San Diego, United States
1859, founded in 2019, is making significant strides in the Biotechnology and Health Care sectors. Operating out of the United States, the company lives up to its slogan, The Origin of Next Generation Medicines, by accelerating drug discovery processes.
With an innovative technology platform that merges combinatorial chemistry, pico-scale activity-based screening, and advanced AI, 1859 generates millions of empirical data points weekly. This wealth of data allows their team of biologists and medicinal chemists to swiftly develop novel small molecule therapeutics, potentially expediting treatments to patients.
Their most recent funding event was a $40.00M Series A, announced on 07 February 2022, with investment support from notable backers such as FusionX Ventures, Northpond Ventures, OMX Ventures, and Vertical Venture Partners. This capital infusion underscores confidence in 1859's cutting-edge approach and potential for transformative impact in healthcare.
Vividion Therapeutics, Inc.
